Slingshot members are tracking this event:

Advancement to Phase 3 Studies of Arhalofenate Dependent on Securing Commercial Partnership

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Data from a Phase 2 study of Arhalofenate was recently released showing positive data from the trial.  However, phase 3 studies will not begin until CymaBay secures a commercial partner for the studies.  Gout is predominately treated by primary care physicians. Therefore, partnering arhalofenate with one or more companies that have a presence in the primary care market is a priority for the Company.  According to a press release, CymaBay is in ongoing discussions with potential partners.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 29, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Clinical Trials, Arhalofenate, Commercial Partnership, Gout, Serum Uric Acid